InnoCare Pharmaceutical Co., Ltd. stock has been added to the Hong Kong Stock Connect stock range
December 26, 2020, Beijing, China - InnoCare Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange Code: 09969), a high-tech biomedical company, announced today that in accordance with relevant regulations, the company's stocks will be included in the scope of Southbound Stock Connect stocks from December 28, 2020.
On December 25, China Investment Information Co., Ltd. issued the "Notice on the Implementation of the First Adjustment for the Inclusion of Specific Types of Company Stocks in the Stock Connect Standards of the Shanghai-Hong Kong Stock Connect", which will include biopharmaceutical companies such as InnoCare Pharmaceutical Co., Ltd.-B (09969) into the list of Hong Kong Stock Connect stocks under the Shanghai-Hong Kong Stock Connect, effective next Monday (December 28).
The notice stated, "In accordance with the relevant provisions of the "Implementation Measures for the Shanghai-Hong Kong Stock Connect Business of the Shanghai Stock Exchange" and the consensus reached by Shanghai-Shenzhen-Hong Kong 3, biotechnology company stocks that meet the conditions for inclusion in the Southbound Connect under the Shanghai-Hong Kong Stock Connect (hereinafter referred to as the Southbound Connect), are listed in accordance with Chapter 18A of the "Main Board Listing Rules" of the Hong Kong Stock Exchange, and have a "B" mark at the end of their stock names will be subject to the first inclusion adjustment, and will be effective from next Monday's Southbound Trading Day."
On the same day, China Chuangying Market Services Co., Ltd. issued the "Announcement on Adjustments to the Southbound Stock Connect Stock List under the Shenzhen-Hong Kong Stock Connect", and added biopharmaceutical companies such as InnoCare Pharmaceutical Co., Ltd.-B (09969) to the Southbound Stock Connect stock list under the Shenzhen-Hong Kong Stock Connect, which will take effect on December 28, 2020 (next Monday).
According to the announcement, in accordance with the relevant provisions of the "Shenzhen Stock Exchange Shenzhen-Hong Kong Stock Connect Business Implementation Measures" and the consensus reached by the Shenzhen-Shanghai-Hong Kong Stock Exchange, the stocks of biotechnology companies listed in accordance with Chapter 18A of the "Main Board Listing Rules" of the Hong Kong Stock Exchange and with a "B" mark at the end of their stock names will be included in the scope of Southbound Stock Connect stocks from December 28, 2020.
At the beginning of 2020, despite the global spread of the epidemic and the complicated capital environment, InnoCare Pharmaceutical Co., Ltd. successfully listed on the Hong Kong Stock Exchange as the first biomedical technology stock on the Hong Kong Stock Exchange in 2020 through the first "cloud gong" method on March 23, thus kicking off this year's biomedical Hong Kong stock listings.
About InnoCare Pharmaceutical Co., Ltd.
InnoCare Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange Code: 09969) is a biopharmaceutical high-tech company in the commercialization stage. It focuses on the development of new drugs in the field of treatment of malignant tumors and autoimmune diseases. It is suitable for a variety of malignant tumors and autoimmune diseases such as lymphoma, liver cancer, cholangiocarcinoma, and urothelial cancer that are highly prevalent in Chinese patients. There are currently multiple new drug products in the commercialization, clinical and preclinical development stages. The company has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey and Boston in the United States.